THE EFFECT OF ENDOPHTHALMITIS ON RECURRENCE OF MACULAR EDEMA IN EYES RECEIVING INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR
| Autor: | Marc J. Spirn, Turner D. Wibbelsman, Philip P Storey, Maitri Pancholy, Brandon Kuley, Samir N Patel, Joshua H Uhr |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Anti vegf
medicine.medical_specialty Retina genetic structures business.industry Growth factor medicine.medical_treatment General Medicine medicine.disease eye diseases 03 medical and health sciences Ophthalmology 0302 clinical medicine medicine.anatomical_structure Choroidal neovascularization Endophthalmitis 030221 ophthalmology & optometry medicine Disease process 030212 general & internal medicine Subretinal fluid medicine.symptom business Macular edema |
| Zdroj: | Retina. 41:1470-1477 |
| ISSN: | 0275-004X |
| DOI: | 10.1097/iae.0000000000003050 |
| Popis: | PURPOSE Visual outcomes after postinjection endophthalmitis have been well-studied, but the effect of endophthalmitis on the underlying exudative disease process remains unclear. We investigate the need for continued anti-vascular endothelial growth factor injections after endophthalmitis. METHODS Eyes that developed endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor between January 1, 2016, and May 31, 2018, at a single academic retina practice were identified. Retrospective chart review was performed to determine 1) the proportion of eyes without recurrence of macular edema or subretinal fluid after endophthalmitis and 2) the proportion achieving a 12-week or greater interval between anti-vascular endothelial growth factor injections or exudation after endophthalmitis compared with internal controls before endophthalmitis. RESULTS Of 50 eyes with endophthalmitis, seven (14.0%) had no fluid recurrence at a mean of 98.1 week. Of 43 eyes with recurrence, 48.0% achieved a >12-week recurrence-free interval after endophthalmitis (vs. 8.3% before endophthalmitis; P < 0.0001). Eyes with compared to those without choroidal neovascularization were more likely to achieve this interval (60.5% vs. 8.3%, respectively; P = 0.002). CONCLUSION Endophthalmitis after anti-vascular endothelial growth factor injection is associated with relative stability of the underlying exudation. Further research is necessary to elucidate the mechanism, which may be useful in developing strategies and targets for the treatment of exudative macular diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|